Topiramate in the treatment of antipsychotic-induced hyperprolactinemia.

Hyperprolactinemia is a common but neglected adverse effect of antipsychotic agents. Current treatments for antipsychotic-induced hyperprolactinemia exert their action mainly through the mechanism of enhancing the inhibitory effect of dopamine on prolactin secretion; however, patients have to endure the risk of psychotic relapse or exacerbation. Topiramate, a new anticonvulsant, is widely used in the treatment of numerous psychiatric conditions. It can antagonize α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and kainate (KA) glutamate receptors and enhance the inhibitory activity of γ-amino butyric acid (GABA). Inhibition of AMPA and KA receptors and increased GABA activity has been proved to have an inhibitory effect on prolactin release. Thus, topiramate may be an effective agent in the treatment of antipsychotic-induced hyperprolactinemia. Copyright © 2020 Elsevier Ltd. All rights reserved.

Citation

Ying-Lin Huang, Miao Peng, Gang Zhu. Topiramate in the treatment of antipsychotic-induced hyperprolactinemia. Medical hypotheses. 2020 May;138:109607

Mesh Tags

Substances

PMID: 32035285

search → result